RXST

Rxsight Inc
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$232.65M
P/E Ratio
EPS
$-1.13
Beta
1.15
52W High
$13.22
52W Low
$4.48
50-Day MA
$5.66
200-Day MA
$8.14
Dividend Yield
Profit Margin
-36.60%
Forward P/E
116.28
PEG Ratio

About Rxsight Inc

Rxsight Inc. is an innovative healthcare technology firm focused on revolutionizing vision correction through state-of-the-art diagnostic and surgical solutions for refractive eye surgery. By leveraging proprietary software and precision laser systems, the company seeks to enhance patient outcomes and overall quality of life for individuals pursuing vision correction options. With a substantial intellectual property portfolio and strategic partnerships in place, Rxsight is well-positioned to capitalize on growth opportunities in the expanding ophthalmic market. Its commitment to innovation and operational excellence underscores the potential for significant advancements within the eye care sector.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$127.48M
Gross Profit (TTM)$98.18M
EBITDA$-52.02M
Operating Margin-57.70%
Return on Equity-17.10%
Return on Assets-11.20%
Revenue/Share (TTM)$3.10
Book Value$6.46
Price-to-Book0.87
Price-to-Sales (TTM)1.82
EV/Revenue0.196
EV/EBITDA-7.70
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-18.50%
Shares Outstanding$41.40M
Float$39.09M
% Insiders6.45%
% Institutions93.14%

Historical Volatility

HV 10-Day
80.64%
HV 20-Day
69.53%
HV 30-Day
67.17%
HV 60-Day
67.04%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($8.43 target)
1
Strong Buy
6
Hold
2
Strong Sell

Latest News

Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE A RXSIGHT, INC. (RXST) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE.What Is The Investigation About?On July 8, 2025, after the market closed, RxSight reported preliminary second quarter.

Business Wire7/8/2026Neutral
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE A RXSIGHT, INC. (RXST) SHAREHOLDER, CLICK HERE TO PARTICIPATE.What Is The Investigation About?On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant.

Business Wire7/7/2026Neutral
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).

GlobeNewsWire7/6/2026Neutral
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company's strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses.

GlobeNewsWire7/6/2026Neutral
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum

ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/.

GlobeNewsWire5/19/2026Neutral
RxSight, Inc. to Present at the Bank of America Healthcare Conference

ALISO VIEJO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., today announced plans to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/.

GlobeNewsWire4/29/2026Neutral
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire4/22/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026